Hypersensitivity Reaction Flashcards
Most common type of Adverse Drug Eruption
Morbilliform
Ig-E mediated type of hypersensitivity reaction
Type 1. Allergic/Anaphylactic
Cytotoxic type of hypersensitivity reaction
Type 2
Cytotoxic
Immune complexes deposited in small vessels activate complement and recruitment of granulocytes
Type 3.
Immune Complex
Cell-mediated type of hypersensitivity reaction
Type 4.
Delayed Type
Examples of Type 1 Hypersensitivity reaction
Urticaria/Angioedema, anaphylactic shock
Examples of Type 2 Hypersensitivity reaction
Petechiae resulting from thrombocytopenic purpura, drug-induced pemphigus
Examples of Type 3 Hypersensitivity reaction
Vasculitis, urticaria, serum sickness
Examples of Type 4 Hypersensitivity reaction
Fixed drug eruption, Lichenoid eruptions, SJS, TEN
Morbilliform eruptions restricted to a previously sunburned site
UV recall-like reaction
Characteristic features of Drug-induced hypersensitivity syndrome
• Rash developing late (>3 weeks) after the inciting
medication is started; often occurs with the first exposure
to the medication
• Long-lasting symptoms (>2 weeks) after discontinuation
of the causative drug
• Fever (>38°C)
• Multiorgan involvement
• Eosinophilia (>1500 absolute eosinophilia); less common
with dapsone (criteria vary, with some groups citing
counts greater than 1500/μl and others more than
700/μl or above 10% if the leukocyte count is lower than
4000/μl)
• Lymphocyte activation (lymphocytosis, atypical
lymphocytosis, lymphadenopathy)
• Frequent reactivation of HHV-6, HHV-7, EBV, and CMV
7 Drugs implicated in DIHS
- Anticonvulsants: phenobarbital, lamotrigine, and
phenytoin - Long-acting sulfonamides: sulfamethoxazole,
sulfadiazine, and sulfasalazine (but not related
medications—sulfonylureas, thiazine diuretics,
furosemide, and acetazolamide) - Allopurinol
- Nevirapine
- Abacavir
- Dapsone
- Minocycline
TBSA involved in SJS
<10 % TBSA
TBSA involved in TEN
> 30% TBSA
Most common sequalae in SJS/TEN
Ocular scarring and vision loss